High-efficiency somatic gene transfer in adult mouse heart has not yet been achieved in vivo. Here, we demonstrate high-efficiency in vivo transcoronary gene delivery to the adult murine myocardium using a catheter-based technique with recombinant adenovirus (AdV) and adeno-associated virus (AAV) vectors in normal and genetically engineered mice. The method involves immersion hypothermia followed by transient aortic and pulmonary artery occlusion with proximal intra-aortic segmental injection of cardioplegic solution containing substance P and viral vectors. Gene expression measured using a LacZ marker gene was observed throughout both ventricles. The expression efficiency of a cytoplasmic LacZ marker gene in the left ventricular myocardium was 56.4714.5% (mean7s.d.) at 4 days with an AdV vector, and with an AAV vector it was 81.075.9% at 4 weeks. Following AAV gene transfer, no gene expression was found in kidney, brain, lung, and spleen, but there was slight expression in liver. In addition, we demonstrate temporally controlled genetic manipulation in the heart with an efficiency of 54.675.2%, by transferring an AdV vector carrying Cre recombinase in ROSA26 floxLacZ reporter mice. Procedure-related mortality was 16% for AdV and zero for AAV transfer. Thus, this method provides efficient, relatively homogeneous gene expression in both ventricles of the adult mouse heart, and offers a novel approach for conditional gene rescue or ablation in genetically engineered mouse models.
Introduction
Many genetically engineered murine models of heart failure have been generated, [1] [2] [3] and crossbreeding experiments have provided insight into potential forms of therapy for heart failure. 4 In addition, ongoing largescale ENU mutagenesis projects in mice will provide expanded mutant mouse resources for research on the pathogenesis of many ultimately fatal diseases. 5 However, elaborate genetic modification, such as conditional mutagenesis or genetic complementation, is significantly hampered by cost and time requirements. Moreover, changes in genetic background often cause phenotypic drift in such animal models. 6 Therefore, study of the cardiac effects of specific gene products would be greatly enhanced if an efficient in vivo cardiac gene delivery system were available for the mouse. In past studies, intravenous injection, intracavitary injection, and intramyocardial injection using virus vectors resulted in insufficient gene expression in left ventricular (LV) myocardium in mice in vivo to test the effects of gene products on global LV function. [7] [8] [9] [10] [11] Although there have been reports of adenovirus (AdV) vector delivery via the aorta in rats 12 and intracoronary AdV vector delivery in rabbits, 13 an efficient transcoronary cardiac gene delivery system has not been established in vivo in adult mice.
Conditional in vivo gene expression and gene deletion are important experimental approaches for examining the functions of specific gene products in development and disease. The Cre-loxP system in transgenic animals has been used to achieve conditional gene activation 14 or deletion (knockout) 15, 16 of targeted genes in myocardium. This application was also demonstrated in the adult mouse with direct intramyocardial injection of AdV encoding Cre recombinase; 11 however, in that report, Cre-mediated recombination was only in focal areas of the LV myocardium. Achievement of highefficiency homogeneous induction of Cre recombination events in the mouse heart could be useful for a number of applications to achieve conditional gene activation or deletion.
One purpose of the current study was to establish a highly efficient in vivo gene transfer method with transcoronary injection using AdV and adeno-associated virus (AAV) vectors in the mouse heart associated with relatively cardiac-specific gene expression. The second goal was to evaluate the potential application of this gene delivery system for conditional cardiac gene deletion using an AdV vector carrying Cre recombinase.
Results

Transcoronary delivery with AdVLacZ
In a study with an AdV vector carrying the cytoplasmic LacZ gene (AdVLacZ) in normal mice (n¼7) there was one procedure-related death after operation. Gene expression at 4 days after transfer was observed throughout the LV, with somewhat lower expression in the right ventricular (RV) side of interventricular septum, and also in the RV myocardium (Figure 1a-c) . Calculated efficiency of expression in LV cardiomyocytes was 56.4714.5% (mean7s.d., range 37.9-71.0%, n¼5). In some mice, expression in the interventricular septum was reduced. Signs of slight inflammation were noted in all AdV-transduced hearts, evidenced by infiltration of a few mononuclear cells in interstitial areas (hematoxylin and eosin staining, data not shown); one animal showed marked inflammation and was excluded from the study (LacZ gene expression in this animal was 5.3%). In all mice, there was a high level of pericentral vein expression in liver (Figure 2d ) (consistent with our previous observations in the hamster), which is con- To assure the adequacy of marker gene expression efficiency, which may be affected by diffusion of the cytoplasmic form of b-galactosidase and X-gal cleavage product, an adenovirus vector carrying a LacZ gene fused with a nuclear-localizing signal (NLSAdVLacZ) was also delivered in C57BL/6 mice (9-10 weeks old, n¼7). There were two procedure-related deaths. Gene expression rate, quantified by point counting of myocytes with nuclei positively stained for b-galactosidase activity in LV myocardium, was 47.277.6% (mean7s.d., range 39.0-55.5%, n¼4, Figure 1d (Figure 2n ). There was mild inflammatory cell infiltration in the heart in one animal, but none in the others.
LV function after gene delivery with AAVLacZ vector
Transthoracic echocardiography was performed in agematched C57BL/6 mice in a normal control group not subjected to gene transfer (n¼8) and in mice at 4 weeks after gene transfer with AAVLacZ (n¼6). LV end-diastolic internal diameter was 3.7470.13 mm (mean7s.d.) in the control group and 3.8570.17 mm in the post gene transfer (GT) group. LV % fractional shortening was 42.571.9% (mean7s.d.) in the control group and 41.971.3% in the post-GT group. No significant differences were identified between the control group and the post-GT group (Table 1) .
Gene deletion with AdV/Cre delivery in ROSA26 mice ROSA26 flox-LacZ reporter mice 17 were subjected to in vivo delivery of an AdV vector carrying the Cre recombinase gene (AdV/Cre). All animals (n¼5, 7-14 weeks old) survived the gene transfer procedure, making the total mortality rate for all AdV gene transfer 16% (n¼19). Organs were harvested and b-galactosidase staining performed 4 days after the AdV/Cre transfer ( Figure 3 ). The Cre-dependent recombination event, determined by b-galactosidase-positive staining, was observed in 54.675.2% (mean7s.d., range 49.9-62.5%, There was slight cell infiltration in the heart indicating minimal immune inflammation in response to the AdV/ Cre vector.
Discussion
In past studies, intravenous injection of AdV vector in neonatal mice resulted in gene expression in 0.2% of cardiac cells, 9 while intracavitary injection of AdV vector in neonatal mice achieved a gene expression efficiency of 11% in ventricular cardiomyocytes. 7 Intramyocardial injections of AdV vector 11 or AAV vector, 8, 10 into the left ventricle of adult mice have produced limited spatial extent of transduction and some evidence of damage in cells surrounding the needle track. In an isolated mouse heart subsequently transplanted to a syngenic host, 15 min of in vitro recirculation of an AAV vector achieved 40% efficiency after 4 weeks. 10 Although there have been reports of AdV-mediated cardiac gene transfer via the aorta in rats 12 and with intracoronary AdV vector transfer in rabbits, 13 efficient cardiac gene transfer has largely failed in the mouse in vivo, because of technical limitations related to the animal size (the body weight: 20-40 g), the organ size (heart weight: 100-200 mg), a very narrow range between toxic and effective doses of vasoactive reagents, and high sensitivity to fluid overload. With our recent success in accomplishing highefficiency in vivo gene transfer in the cardiomyopathic hamster heart using AdV 18 and AAV vectors, 19 as well as our extensive use of microsurgical techniques and miniaturized methods for assessing cardiac function in the mouse, [20] [21] [22] we undertook to determine whether a modified approach would be feasible for application in the mouse.
In the present study, using microsurgical methods we could safely occlude the aorta using hypothermia to protect vital organs and achieve cardiac gene transfer during transient cardiac arrest coupled with increased capillary permeability. Without aortic occlusion or without use of a vascular permeabilizing agent, efficiency was low (data not shown). The method ultimately devised for transcoronary gene delivery achieved efficient short-term gene expression with AdV vectors, and using an AAV vector high efficiency with relatively cardiac-restricted gene expression was feasible at 4 weeks after delivery. It should be noted that other strategies for achieving tissue-specific in vivo expression of functional genes in adult mice have had limitations. Gene expression studies in transgenic mice using the aMHC promoter have been used frequently; however, without temporal control, complications of interpretation are introduced by pre-existing phenotypes produced by early gene expression driven by the aMHC promoter at embryonic or early postnatal stages. 23, 24 Nonspecific effects using the aMHC promoter have also been reported. 25 More sophisticated temporal manipulation of cardiac gene expression has been attempted, including the tetracycline-controlled transactivator system 26 and drug-sensitive Cre systems, 27, 28 although the tightness of regulation of these complicated genetic manipulations has been questioned; as noted, mosaic gene activation and preintervention leakage are not unusual events. In addition, these elaborate genetic engineering strategies are costly and time-consuming. Accordingly, our in vivo gene delivery system provides a novel competent strategy to test functional genes, or genes with specific mutations, in normal or existing wellcharacterized murine models of cardiac disease, such cardiomyopathic mice with the muscle-specific LIM protein deficiency. 21 Conditional in vivo gene expression and gene deletion are important experimental approaches for examining the functions of specific gene products in development and disease. The Cre-loxP system in transgenic animals has been used to achieve conditional gene activation 14 or deletion (knockout) 15, 16 of targeted genes in myocardium. Generally, this system requires cross-breeding of two lines of transgenic animals, one carrying an allele with the locus of interest flanked by two loxP sequences and the other carrying a Cre transgene in which the expression of the Cre protein is controlled by a heterologous tissue-specific promoter, 11 or in some cases Cre is knocked-in to the coding 14, 15 or 3 0 noncoding region of tissue-specific genes with an internal ribosome entry site. 29 Recombination between the loxP elements in the offspring is dependent upon the expression pattern of the Cre transgene, defined by the specificity of promoters or other locus-specific transcriptional regulation. 30 Cre-mediated recombination can also be regulated by controlling the timing of Cre activation, 31, 32 and conditional, drug-induced post-translational activation of Cre recombination can bypass potential embryonic and prenatal effects on the heart. 26, 27 This application was also demonstrated in the mouse with direct intramyocardial injection of AdV encoding Cre recombinase; 11 however, as noted, Cre-mediated recombination was only in focal areas of the left ventricle.
In the current study, an AdV/Cre vector was employed in ROSA26 reporter mice to further substantiate the value of this gene delivery system. The ROSA26 flox-LacZ reporter mouse were originally generated by P Soriano 17 and harbors an inactivated LacZ gene at the ROSA26 locus with a floxed stopper sequence. This mouse is widely used to detect in vivo activity of Cre recombinase, which enzymatically deletes the stopper sequence to activate the downstream LacZ gene. Using the ROSA26 reporter mice with transcoronary AdV/Cre delivery, we were able to achieve high efficiency with nearly homogenous induction of genetic recombination events in the heart, indicating that this type of technology could be useful for achieving conditional gene activation or deletion in other floxed transgenic mice, which are widely available in the research community.
In conclusion, our approach offers efficient in vivo gene expression throughout the left ventricle of the mouse heart, with relatively cardiac-specific and sustained gene expression using the rAAV vector. Lower expression also occurs in the right ventricle and atria. This approach will allow examination of the effects of gene products on global heart function in the adult mouse, and it offers a new approach for conditional gene rescue and ablation in genetically engineered mouse models.
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Materials and methods
Background studies to optimize optimal gene delivery in the mouse Our initial efforts to apply hypothermia (external body cooling) with brief aortic and pulmonary artery occlusion accompanied by transient cardiac arrest and aortic root injection of AdV vectors in the presence of histamine, as used effectively in the hamster, 18, 19 were not successful and carried extremely high early and late mortality rates. Accordingly, we assessed a series of vascular permeabilizing agents other than histamine and found that substance P (SP) 33 was well tolerated by the mouse. Gene expression rate with 2 ng SP was 41.179.8% (mean7s.d., n¼4), with 5 ng SP it was 56.4714.5% (n¼5), and with 100 ng SP it was 28.272.5% (n¼2); the latter dose and an even higher dose prolonged recovery time; so a total dose of 5 ng was used in all subsequent experiments. The volume and composition of the cardioplegic (CP) solutions proved important to obtain a sufficient period of cardiac arrest for efficient gene expression. CP solution with 20 mM KCl (CP20) did not stop the heartbeat for more than 30 s, and CP solution with 25 mM KCl (CP25) was sufficient to cause 45 s or more of cardiac arrest. A virus delivery volume of 75 ml was also found to be optimal (50 ml volume of CP solution was too little to sustain arrest and 100 ml was not tolerated by C57BL/6 mice (mean body weight 23. 972.1 g) ). The sequence of occluding the pulmonary artery (PA) first followed immediately by the ascending aorta (Ao) proved to have an advantage in homogeneous distribution of gene expression in the LV myocardium. The sequence of the Ao occlusion followed by the PA occulusion, used in the hamster, 18, 19 decreased gene expression in LV endocardium, presumably due to higher intracavitary LV pressure. Finally, our standard use of intraperitoneal anesthesia ketamine (100 mg/kg)/ xylazine (5 mg/kg) was found to be responsible for delayed recovery and increased late mortality (30%) in the mouse (n¼20). A single initial low dose of intraperitoneal anesthetic followed by maintenance inhalation anesthesia with isoflurane and O 2 greatly hastened recovery and improved survival.
In vivo delivery method in mice C57BL/6 mice (n¼28, 9-17 weeks old from Charles River Laboratory, Wilmington, MA, USA) were included in this study. Of these, eight mice served as normal controls for echocardiographic studies. Following a single low dose of ketamine (50 mg/kg) and xylazine (2.5 mg/kg), the mice are intubated and ventilated with a pressurecontrolled respirator (RSP1002, Kent Scientific Corporation, CT, USA) at a respiratory rate of 100/min, 35% inspiratory time, and 15 cm of water inspiratory cutoff pressure; they were then maintained on 0.5-2.0% isoflurane in O 2 . Through a small left anterior first intercostal space chest incision, snares are placed around the Ao and PA using 6-0 silk surgical suture. Following cannulation of the right carotid artery with a flamestretched PE-60 polyethylene tube (Intramedics), the catheter tip is positioned above the aortic valve for blood pressure measurement and subsequent injections into the aortic root, and crushed ice is applied around the body to bring the rectal temperature to 19.0-21.51C (Figure 4a) . The PA is then occluded followed quickly by the Ao (Figure 4a) . Three injections are then made into the proximal aortic root: (1) CP solution (NaCl 110, KCl 10, CaCl 2 1.2, MgCl 2 16, and NaHCO 3 10, in mM) and 2 ng SP (volume injected: 100 ml); (2) 3 s later CP solution Figure 4 In vivo transcoronary gene transfer procedure (a) and measurement method for gene expression rate in LV myocardium with point-counting method (b, c). (a) The details of the procedure are described in 'Materials and methods'. Briefly, following immersion whole-body hypothermia, the PA and Ao are sequential occluded, and three injections are then made into the proximal aortic root to achieve arrest of the heart with CP and to increase vascular permeability with SP followed by injection of the viral vector in CP and SP solution. The Ao and PA snares are then released 45 s after the final injection, dobutamine is infused through the aortic catheter, and animals are warmed to normal body temperature. (Figure 4a ). Dobutamine is then infused through the aortic catheter (20 mg/kg/min), with gentle chest compression if necessary; the mouse is then placed on a warming pad and, when systolic arterial pressure reaches 65-70 mmHg, extubation is usually feasible within 15 min and the animal is allowed to recover. All protocols were approved by the University of California, San Diego Animal Subjects Committee.
In vivo delivery of AdV/Cre vector in ROSA26 indicator mice ROSA26 flox-LacZ reporter mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA) (n¼5, 7-14 weeks old) and subjected to in vivo AdV/ Cre delivery.
Preparation and dose of virus vectors
Replication-deficient AdVLacZ vectors containing either a cytoplasmic LacZ gene or a modified LacZ gene fused to a nuclear-localizing signal (NLSAdVLacZ) were used. Also a Cre recombinase AdV vector was prepared. The titer of each vector preparation was determined as described previously. 34 An AAVLacZ vector containing a cytoplasmic b-galactosidase transgene was prepared 35, 36 and supplied by Drs Lili Wang and James M Wilson (University of Pennsylvania, Philadelphia, PA, USA). The infectious units (IU) of AAVLacZ were determined as previously described. 36 In the mice, the following constructs were delivered: cytoplasmic AdVLacZ with 9.2 Â 10 10 virus particles (4.9 Â 10 12 virus particles/ml, 3.8 Â 10 10 PFU/ml), or NLSAdVLacZ with 9.2 Â 10 10 virus particles (1.6 Â 10 12 virus particles/ml, 1.2 Â 10 10 PFU/ml) or AdV/Cre vector with 1.7 Â 10 10 virus particles (2.3 Â 10 12 virus particles/ml, 2.5 Â 10 11 PFU/ml) or AAVLacZ with 9.2 Â 10 10 genome copies (2.5 Â 10 12 genome copies/ml, 1.7x10 10 IU/ml).
b-Galactosidase staining for determining expression efficiency
The heart and other organs were harvested at 4 days after AdVLacZ, NLSAdVLacZ and AdV/Cre gene transfer and at 4 weeks after AAVLacZ gene transfer. The heart was sliced transversely into three pieces, mounted in OCT compound and frozen. Cross-sections from the mid-LV and apical slices were used for bgalactosidase staining. For b-galactosidase staining, sections from hearts transfected with AdVLacZ, NLS AdVLacZ or AAVLacZ were fixed with 0.4% glutaraldehyde for 5 min at room temperature and incubated in X-Gal solution for 3 h at 371C; sections from hearts transfected with AdV/Cre were incubated overnight. Sections were counterstained with neutral red and fixed with 4% paraformaldehyde. A total of eight randomly selected areas around the LV in both the apical (n¼4) and mid level (n¼4) LV slices were selected for imaging and photomicroscopy at Â 200 magnification (437 mm Â 582 mm), and two areas were selected at the mid-RV level. Gene expression was quantified by point-counting 18 of cardiomyocytes with cytoplasmic staining of bgalactosidase activity (cytoplasmic LacZ, Figure 4b ) or cells with positive b-galactosidase nuclei (nuclear localizing LacZ, Figure 4c ) using a grid (18.2 Â 18.2 mm in each side; 713 intersections in each image), and the percentage of positive points from the eight images were averaged for LV and two images for RV in each animal. Only intersections on cardiomyocytes were identified as positive or negative (Figure 4b and c) .
Echocardiography
Transthoracic echocardiography was performed as previously described 20 in age-matched C57BL/6 mice in a control, nonoperated group (n¼8) and in mice at 4 weeks after gene transfer with AAVLacZ (n¼6). Mice were anesthetized with intraperitoneal injection of 2.5% tribromoethanol (Avertin; 12 ml/g). Unpaired t-tests were performed to compare the two groups.
